Karyopharm Therapeut (KPTI) Stock Price, Quote & News

Company Profile

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for th...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 658 0600

Website: www.karyopharm.com

Address:

85 Wells Avenue, 2nd Floor, Suite 210, Newton, United States

celebratelife Sep. 11 at 9:27 PM

$KPTI SO LONG LOUSY USELESS DO-NOTHING DIRECTOR MANSOOR MIRZA. WE WON'T MISS YOU FOR A SECOND. https://x.com/karyowatch/status/1966252117020258705

0 · Reply

AlexPEC Sep. 11 at 1:53 PM

$KPTI

0 · Reply

celebratelife Sep. 10 at 7:34 PM

$KPTI SEEMINGLY UNETHICAL VALUE-DESTROYERS RUN & PROFIT FROM KPTI AT OUR COST https://x.com/karyowatch/status/1965860944908792202

0 · Reply

BioTuesdays Sep. 10 at 2:52 PM

$KPTI has announced enrollment completion in its Phase 3 SENTRY trial, designed to evaluate selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis (MF) patients https://biotuesdays.com/2025/09/10/karyopharm-completes-enrollment-of-phase-3-sentry-trial-in-mf/

0 · Reply

Watson66 Sep. 10 at 12:13 PM

$KPTI https://finance.yahoo.com/news/karyopharm-announces-completion-enrollment-phase-110000546.html

0 · Reply

Thestocktraderhubzee Sep. 10 at 11:08 AM

WATCHLIST SEP 10 2025 $IMRX Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25 $KPTI Karyopharm Completes Enrollment In Phase 3 Trial Testing New Combo Therapy For Myelofibrosis Patients $KIDS OrthoPediatrics Surgeons Perform First Procedures With VerteGlide System Providing Breakthrough Growth Guidance Technology For Children With Early Onset Scoliosis $BHST BioHarvest Sciences Announces Breakthrough in Botanical Synthesis Capabilities with Plant-Based Exosome Production at Scale $TVTX Travere Therapeutics Announces FDA Drops Advisory Committee For FILSPARI sNDA In FSGS; PDUFA Target Date Set For January 13, 2026

0 · Reply

celebratelife Sep. 9 at 7:55 PM

$KPTI Firing Paulson: the most critical milestone for the company https://x.com/karyowatch/status/1965503358875361619

0 · Reply

cert Sep. 8 at 2:31 PM

$KPTI why is this down so much ? any latest news released ? Thanks in advance for the insight

2 · Reply

longrigger52 Sep. 7 at 12:33 AM

$KPTI tick tock….tick tock……how many days to extinction?? what happened to handshake deal after such ” apparat confidence” in all conf calls rp a great con man despite his bleak aura

0 · Reply

celebratelife Sep. 6 at 8:56 PM

$KPTI WARNING TO THESE SELF-SEVING, LAZY, IRRESPONSIBLE, INCOMPETENT BUMS: https://x.com/karyowatch/status/1964432150486520294

0 · Reply

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

Sep 2, 2025, 4:05 PM EDT - 9 days ago

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 11, 2025, 11:02 AM EDT - 4 weeks ago

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 7:30 AM EDT - 4 weeks ago

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

Aug 5, 2025, 7:00 AM EDT - 5 weeks ago

Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025

Jun 3, 2025, 8:00 AM EDT - 3 months ago

Karyopharm to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 7:00 AM EDT - 4 months ago

Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:31 AM EDT - 4 months ago

Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting

May 13, 2025, 1:39 PM EDT - 4 months ago

These Analysts Revise Their Forecasts On Karyopharm Therapeutics After Q1 Results

May 13, 2025, 7:15 AM EDT - 4 months ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:05 PM EDT - 4 months ago

Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification

May 8, 2025, 4:05 PM EDT - 4 months ago

Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025

Mar 5, 2025, 12:00 AM EST - 6 months ago

XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC

Feb 24, 2025, 8:40 AM EST - 7 months ago

Karyopharm Announces 1-for-15 Reverse Stock Split

Feb 19, 2025, 11:05 AM EST - 7 months ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:30 AM EST - 7 months ago

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress

Feb 13, 2025, 4:30 AM EST - 7 months ago

Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region

Feb 12, 2025, 7:00 AM EST - 7 months ago

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Jan 13, 2025, 8:30 AM EST - 8 months ago

Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives

Jan 2, 2025, 7:00 AM EST - 9 months ago

Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer

Dec 9, 2024, 8:00 AM EST - 9 months ago

Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications

Dec 3, 2024, 7:00 AM EST - 10 months ago

Karyopharm Therapeutics Provides Endometrial Cancer Program Update

Nov 25, 2024, 7:00 AM EST - 10 months ago

Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 4:05 PM EST - 10 months ago

Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer

Nov 18, 2024, 7:00 AM EST - 10 months ago

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition

Nov 5, 2024, 9:22 PM EST - 11 months ago

Karyopharm Therapeutics Inc. (KPTI) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:30 PM EST - 11 months ago

Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024

Nov 5, 2024, 7:30 AM EST - 11 months ago

Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Oct 31, 2024, 8:00 AM EDT - 11 months ago

Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024

Oct 31, 2024, 7:30 AM EDT - 11 months ago

Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis

Oct 30, 2024, 4:30 PM EDT - 11 months ago

Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024

Oct 17, 2024, 10:35 PM EDT - 11 months ago

Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country

Sep 23, 2024, 5:00 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Karyopharm to Participate at Upcoming Investor Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress

Aug 5, 2024, 8:00 PM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024

Jul 5, 2024, 9:10 AM EDT - 1 year ago

XPOVIO® (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country

Jun 26, 2024, 4:42 AM EDT - 1 year ago

Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea

Jun 1, 2024, 1:45 PM EDT - 1 year ago

Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates

May 29, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the Jefferies Global Healthcare Conference

May 8, 2024, 4:05 PM EDT - 1 year ago

Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 3:38 PM EDT - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029

May 8, 2024, 7:30 AM EDT - 1 year ago

Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 2, 2024, 4:30 PM EDT - 1 year ago

Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 30, 2024, 2:28 PM EDT - 1 year ago

Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts

Apr 24, 2024, 4:01 PM EDT - 1 year ago

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting

Mar 6, 2024, 4:05 PM EST - 1 year ago

Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences

Feb 29, 2024, 11:26 AM EST - 1 year ago

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

celebratelife Sep. 11 at 9:27 PM

$KPTI SO LONG LOUSY USELESS DO-NOTHING DIRECTOR MANSOOR MIRZA. WE WON'T MISS YOU FOR A SECOND. https://x.com/karyowatch/status/1966252117020258705

0 · Reply

AlexPEC Sep. 11 at 1:53 PM

$KPTI

0 · Reply

celebratelife Sep. 10 at 7:34 PM

$KPTI SEEMINGLY UNETHICAL VALUE-DESTROYERS RUN & PROFIT FROM KPTI AT OUR COST https://x.com/karyowatch/status/1965860944908792202

0 · Reply

BioTuesdays Sep. 10 at 2:52 PM

0 · Reply

Watson66 Sep. 10 at 12:13 PM

$KPTI https://finance.yahoo.com/news/karyopharm-announces-completion-enrollment-phase-110000546.html

0 · Reply

Thestocktraderhubzee Sep. 10 at 11:08 AM

0 · Reply

celebratelife Sep. 9 at 7:55 PM

$KPTI Firing Paulson: the most critical milestone for the company https://x.com/karyowatch/status/1965503358875361619

0 · Reply

cert Sep. 8 at 2:31 PM

$KPTI why is this down so much ? any latest news released ? Thanks in advance for the insight

2 · Reply

longrigger52 Sep. 7 at 12:33 AM

$KPTI tick tock….tick tock……how many days to extinction?? what happened to handshake deal after such ” apparat confidence” in all conf calls rp a great con man despite his bleak aura

0 · Reply

celebratelife Sep. 6 at 8:56 PM

$KPTI WARNING TO THESE SELF-SEVING, LAZY, IRRESPONSIBLE, INCOMPETENT BUMS: https://x.com/karyowatch/status/1964432150486520294

0 · Reply

celebratelife Sep. 5 at 8:32 PM

$KPTI Big $$$$$$ for lousy management https://x.com/karyowatch/status/1964063919179169912

0 · Reply

celebratelife Sep. 5 at 7:43 PM

$KPTI down 99% since the wicked, self-serving, value-destroyer Richard Paulson joined the company. Chart: https://x.com/karyowatch/status/1964051567348449352

0 · Reply

celebratelife Sep. 5 at 1:51 PM

$KPTI can Paulson turnaround a highschool snack-bar? https://x.com/karyowatch/status/1963962775702589477

0 · Reply

celebratelife Sep. 4 at 11:00 PM

$KPTI Management Ineptness Has Cost Us Hundreds of Millions https://x.com/karyowatch/status/1963738811378418063

0 · Reply

celebratelife Sep. 4 at 7:34 PM

$KPTI Extremely low volume. Anticipation mode.

0 · Reply

longrigger52 Sep. 4 at 12:16 PM

$KPTI such an arrogant company after you struggle to enroll trials for years, u go silent when you finally do complete enrollment. This crew deserves to just go away

1 · Reply

seforim Sep. 4 at 11:05 AM

$KPTI https://x.com/kinatsofrim/status/1963335914861822307

0 · Reply

celebratelife Sep. 4 at 4:08 AM

$KPTI GOOD NEWS: SENTRY P3 enrollment finally complete https://x.com/karyowatch/status/1963453901274829086

0 · Reply

celebratelife Sep. 3 at 7:51 PM

$KPTI Burning money in Texas https://x.com/karyowatch/status/1963328499550409112

0 · Reply

celebratelife Sep. 3 at 1:15 PM

$KPTI The crooks are painting the tape with 300 shares pre-market. That's a buy signal to me!

0 · Reply

celebratelife Sep. 3 at 5:16 AM

$KPTI big test for stock: https://x.com/karyowatch/status/1963108342475219325

0 · Reply

celebratelife Sep. 3 at 5:15 AM

$KPTI chat - 80% of the volume: https://x.com/karyowatch/status/1963107881512738817

0 · Reply

Market Cap	53.85M
Revenue (ttm)	145.24M
Net Income (ttm)	-76.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-52.62%
Debt to Equity Ratio	-0.50

Volume	46,100
Avg Vol	194,120
Day's Range	N/A - N/A
Shares Out	8.67M
Stochastic %K	47%
Beta	0.35
Analysts	Strong Sell
Price Target	$17.60